CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
0.5800
-0.0558 (-8.78%)
At close: Apr 1, 2025, 4:00 PM
0.5846
+0.0046 (0.79%)
After-hours: Apr 1, 2025, 4:48 PM EDT
CytomX Therapeutics Stock Forecast
CTMX's stock price has decreased by -73.39% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for CytomX Therapeutics stock have an average target of 5.77, with a low estimate of 3.50 and a high estimate of 8.00. The average target predicts an increase of 894.83% from the current stock price of 0.58.
Analyst Consensus: Buy
* Price targets were last updated on May 28, 2024.
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 7, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 7, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 11, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 22, 2024 |
Financial Forecast
Revenue This Year
77.80M
from 138.10M
Decreased by -43.67%
Revenue Next Year
34.35M
from 77.80M
Decreased by -55.85%
EPS This Year
0.10
from 0.38
Decreased by -73.79%
EPS Next Year
-0.50
from 0.10
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 138.6M | 88.9M | 84.2M | ||
Avg | 77.8M | 34.3M | 44.3M | ||
Low | 30.4M | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 0.4% | 14.3% | 145.2% | ||
Avg | -43.7% | -55.8% | 28.9% | ||
Low | -78.0% | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 0.79 | 0.15 | -0.53 | |
Avg | 0.10 | -0.50 | -0.65 | |
Low | -0.43 | -0.99 | -0.83 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 108.7% | 48.6% | - | |
Avg | -73.8% | - | - | |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.